Ablashi, D V, Eastman, H B, Owen, C B et al. · Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2000 · DOI
This study looked at whether a common virus called HHV-6 might be reactivated in ME/CFS patients. Researchers found that ME/CFS and MS patients had higher levels of antibodies (immune markers) to HHV-6 compared to healthy people, and they detected active virus in blood cells from these patients. The findings suggest that HHV-6 reactivation might play a role in causing or worsening ME/CFS symptoms.
This study provides early evidence that HHV-6 reactivation may contribute to ME/CFS pathogenesis rather than simply being an incidental finding. Understanding viral reactivation mechanisms could open new diagnostic and therapeutic avenues for ME/CFS patients who currently lack biomarkers and disease-modifying treatments.
This study does not prove that HHV-6 reactivation causes ME/CFS, only that it is more frequently detected in patients. The cross-sectional design cannot establish temporal relationships or distinguish whether viral reactivation is a primary driver of disease or a consequence of immune dysfunction. It also does not clarify whether HHV-6 reactivation is sufficient to cause ME/CFS or simply a contributing factor.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →